We understand that starting a new medication can be daunting, and our team is dedicated to providing guidance and support to manage any potential side effects, such as nausea or gastrointestinal discomfort, ensuring a smooth transition for our patients
The participants were divided into five treatment groups: bofanglutide 12 mg (biweekly) bofanglutide 18 mg (biweekly) bofanglutide 24mg (biweekly) bofanglutide 24mg (once weekly) semaglutide 1mg (once weekly) The primary measurement the researchers focused on was HbA1c levels from the baseline to the 24-week follow-up
My cravings are way more manageable, and my energy levels feel steadier throughout the day
However, as of this articles publication date, no peptide-based oral GLP-1 has received approval specifically for weight management
Achieving and maintaining a healthy weight can be challenging, especially with busy lifestyles and the many factors that impact metabolism and appetite
CMS Extends Medicares Short-Term Bridge Program for GLP-1 Obesity Drug Coverage The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on January 1, 2027